Hengrui Medicine: Will grant GSK paid exclusive rights to the global exclusive licenses of up to 11 projects.

Hengrui Pharmaceuticals announced that the company has reached an agreement with GSK to grant GSK paid exclusive rights to the global exclusive license for the HRS-9821 project and the exclusive option to license up to 11 projects globally. GSK will pay Hengrui a down payment of $500 million, with the company eligible to receive a potential total of approximately $12 billion in future milestone payments based on successful development, registration, and sales.